SAREPTA THERAPEUTICS, INC. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
SAREPTA THERAPEUTICS, INC. (SRPT) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$14.26 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-03.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2018-05-03
- SAREPTA THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2018-03-31 was -$14.26M, a 106.79% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-12-31 was -$493.69M.
- SAREPTA THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-09-30 was $124.95M, a 1122.11% increase year-over-year.
- SAREPTA THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-06-30 was -$20.05M, a 125.41% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2017 was -$178.81M.
- SAREPTA THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was -$90.19M, a 1172.45% decline from fiscal 2015.
- SAREPTA THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was $8.41M.
- SAREPTA THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$159.03M.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 404 month |
|---|---|---|---|---|---|
| 2018-03-31 | -$14.26M 10-Q · filed 2018-05-03 | -$507.95M derived: sum of 2 quarters · filed 2018-05-03 | -$383.01M derived: sum of 3 quarters · filed 2018-05-03 | -$403.06M derived: sum of 4 quarters · filed 2018-05-03 | |
| 2017-12-31 | -$493.69M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | -$368.75M derived: sum of 2 quarters · filed 2018-03-01 | -$388.80M derived: sum of 3 quarters · filed 2018-03-01 | -$178.81M 10-K · filed 2018-03-01 | |
| 2017-09-30 | $124.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $104.89M derived: sum of 2 quarters · filed 2017-11-01 | $314.88M 10-Q · filed 2017-11-01 | $116.11M derived: sum of 4 quarters · filed 2018-05-03 | |
| 2017-06-30 | -$20.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $189.93M 10-Q · filed 2017-08-03 | -$8.84M derived: sum of 3 quarters · filed 2018-05-03 | $1.38M derived: sum of 4 quarters · filed 2018-05-03 | |
| 2017-03-31 | $209.99M 10-Q · filed 2018-05-03 | $11.21M derived: sum of 2 quarters · filed 2018-05-03 | $21.43M derived: sum of 3 quarters · filed 2018-05-03 | $100.37M derived: sum of 4 quarters · filed 2018-05-03 | |
| 2016-12-31 | -$198.77M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | -$188.55M derived: sum of 2 quarters · filed 2018-03-01 | -$109.61M derived: sum of 3 quarters · filed 2018-03-01 | -$90.19M 10-K · filed 2018-03-01 | |
| 2016-09-30 | $10.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $89.16M derived: sum of 2 quarters · filed 2017-11-01 | $108.58M 10-Q · filed 2017-11-01 | $38.76M derived: sum of 4 quarters · filed 2018-03-01 | |
| 2016-06-30 | $78.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $98.36M 10-Q · filed 2017-08-03 | $28.54M derived: sum of 3 quarters · filed 2018-03-01 | $59.56M derived: sum of 4 quarters · filed 2018-03-01 | |
| 2016-03-31 | $19.42M 10-Q · filed 2017-05-04 | -$50.40M derived: sum of 2 quarters · filed 2018-03-01 | -$19.38M derived: sum of 3 quarters · filed 2018-03-01 | -$15.99M derived: sum of 4 quarters · filed 2018-03-01 | |
| 2015-12-31 | -$69.82M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | -$38.80M derived: sum of 2 quarters · filed 2018-03-01 | -$35.42M derived: sum of 3 quarters · filed 2018-03-01 | $8.41M 10-K · filed 2018-03-01 | |
| 2015-09-30 | $31.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $34.40M derived: sum of 2 quarters · filed 2016-11-07 | $78.23M 10-Q · filed 2016-11-07 | $124.91M derived: sum of 4 quarters · filed 2017-02-28 | |
| 2015-06-30 | $3.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $47.21M 10-Q · filed 2016-08-09 | $93.89M derived: sum of 3 quarters · filed 2017-02-28 | $73.35M derived: sum of 4 quarters · filed 2017-02-28 | |
| 2015-03-31 | $43.83M 10-Q · filed 2016-05-05 | $90.50M derived: sum of 2 quarters · filed 2017-02-28 | $69.96M derived: sum of 3 quarters · filed 2017-02-28 | $67.09M derived: sum of 4 quarters · filed 2017-02-28 | |
| 2014-12-31 | $46.68M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $26.14M derived: sum of 2 quarters · filed 2017-02-28 | $23.26M derived: sum of 3 quarters · filed 2017-02-28 | -$159.03M 10-K · filed 2017-02-28 | |
| 2014-09-30 | -$20.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | -$23.42M derived: sum of 2 quarters · filed 2015-11-05 | -$205.71M 10-Q · filed 2015-11-05 | -$206.53M derived: sum of 4 quarters · filed 2016-02-25 | |
| 2014-06-30 | -$2.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | -$185.17M 10-Q · filed 2015-08-06 | -$185.99M derived: sum of 3 quarters · filed 2016-02-25 | -$187.66M derived: sum of 4 quarters · filed 2016-02-25 | |
| 2014-03-31 | -$182.29M 10-Q · filed 2015-05-07 | -$183.11M derived: sum of 2 quarters · filed 2016-02-25 | -$184.79M derived: sum of 3 quarters · filed 2016-02-25 | -$186.24M derived: sum of 4 quarters · filed 2016-02-25 | -$222.13M 10-Q · filed 2014-05-08 |
| 2013-12-31 | -$822.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25 | -$2.50M derived: sum of 2 quarters · filed 2016-02-25 | -$3.95M derived: sum of 3 quarters · filed 2016-02-25 | -$11.67M 10-K · filed 2016-02-25 | |
| 2013-09-30 | -$1.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | -$3.13M derived: sum of 2 quarters · filed 2014-11-06 | -$10.85M 10-Q · filed 2014-11-06 | ||
| 2013-06-30 | -$1.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | -$9.17M 10-Q · filed 2014-08-07 | |||
| 2013-03-31 | -$7.72M 10-Q · filed 2014-05-08 | ||||
| 2012-12-31 | -$1.15M 10-K · filed 2015-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |